Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

The purpose of the study is to assess the effects of rifampin on the pharmacokinetics of dapagliflozin

Inclusion Criteria:

• Healthy subjects
• Body Mass Index (BMI) of 18 to 32 inclusive
• Women who are not of childbearing potential and men, ages 18 to 45

Exclusion Criteria:

• Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, electrocardiogram (ECG) or clinical laboratory determinations
• Glucosuria
• Abnormal liver function tests